USANA (USNA) Q3 2026 Earnings Call Transcript
USANA (USNA) reported Q3 2026 earnings, highlighting improvements in Core Nutrition profitability and Hiya's subscriber growth. Net sales grew 2% YoY in Southeast Asia Pacific, while Hiya added 29,500 subscribers. The company raised Hiya's net sales outlook to $130M but lowered Rise Wellness's outlook. Full-year net sales are expected to approach $900M with adjusted EBITDA of $77M. USANA remains debt-free with $179M in cash.
How this was made
The 30-second read
Why it matters
The revised sales and EBITDA outlook provides fresh quantitative data that can shift investor expectations and drive short‑term price movement.
Market read
New guidance from a listed health‑supplement company offers a clear trading catalyst, especially in after‑hours markets.
What to watch
Weakness in Rise Wellness and declining active customers could offset upside from Hiya growth.
Background
USANA's Q3 2026 earnings call covered performance across its Core Nutrition, Hiya, and Rise Wellness segments, highlighting a mixed picture of growth and challenges.
Ticker impact
USANA provided Q3 2026 net sales outlook of $900M and adjusted EBITDA of $77M, revising prior guidance.
likely upward pressure as market prices in higher earnings expectations
The company lifted its sales and EBITDA outlook on the earnings call, a fresh primary disclosure that can move the share price in after‑hours trading.
Market effects
Improves outlook for the nutrition and wellness sector, may lift peers with similar business models.
Positive for US‑based health‑supplement companies; limited impact outside North America.
Modest, confined to specialty nutrition niche.
Counterpoint
Guidance raise may already be priced in; execution risk remains high given active‑customer decline.
Key entities
- CompanyUSANA Health Sciences
US‑listed nutrition and supplement maker (ticker USNA).
